【標(biāo)題速讀】【Nm】【2022年】【7-12月】
聲明：本專欄主要對生命科學(xué)領(lǐng)域的一些期刊文章標(biāo)題進(jìn)行翻譯，所有內(nèi)容均由本人手工整理翻譯。由于本人專業(yè)為生物分析相關(guān)，其他領(lǐng)域如果出現(xiàn)翻譯錯誤請諒解。
Two papers by Saria and colleagues in this issue report results from the prospective evaluation of deployment of a machine learning–based early warning system for sepsis in five hospitals. The cover depicts elements of the integrated artificial intelligence platform that expands the capacity of healthcare providers to visualize and interpret signs of deterioration associated with sepsis, leading to opportunities for early intervention and improved patient outcomes.
Saria及其同事在本期中發(fā)表的兩篇論文報告了對五家醫(yī)院部署基于機(jī)器學(xué)習(xí)的敗血癥早期預(yù)警系統(tǒng)的前瞻性評估結(jié)果。封面描述了集成人工智能平臺的元素，該平臺擴(kuò)展了醫(yī)療保健提供者可視化和解釋與敗血癥相關(guān)的惡化跡象的能力，從而為早期干預(yù)和改善患者預(yù)后提供了機(jī)會。
1.Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Onasemnogene abeparvovec治療有兩個SMN2拷貝的無癥狀嬰兒，有患脊髓性肌肉萎縮癥1型的風(fēng)險：III期SPR1NT試驗。
2.Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
Onasemnogene abeparvovec治療有三個SMN2拷貝的無癥狀嬰兒，有脊柱肌萎縮的風(fēng)險：III期SPR1NT試驗。
3.Performance of plasma phosphorylated tau 181 and 217 in the community.
社區(qū)中血漿磷酸化tau181和217的表現(xiàn)。
4.Parental inflammatory bowel disease and autism in children.
父母的炎癥性腸病和兒童自閉癥。
5.Genome-wide polygenic score to predict chronic kidney disease across ancestries.
全基因組多基因評分預(yù)測跨血統(tǒng)的慢性腎臟病。
6.A T cell resilience model associated with response to immunotherapy in multiple tumor types.
一種與多種腫瘤類型的免疫療法反應(yīng)有關(guān)的T細(xì)胞復(fù)原力模型。
7.Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
利格列凈治療非酒精性脂肪性肝炎：一項隨機(jī)、雙盲、安慰劑對照的2a期研究。
8.Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects.
克隆造血的縱向動力學(xué)確定了基因特定的健身效果。
9.Factors driving provider adoption of the TREWS machine learning-based early warning system and its effects on sepsis treatment timing.
推動供應(yīng)商采用基于機(jī)器學(xué)習(xí)的TREWS預(yù)警系統(tǒng)的因素及其對敗血癥治療時機(jī)的影響。
10.Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis.
基于TREWS機(jī)器學(xué)習(xí)的敗血癥早期預(yù)警系統(tǒng)實施后的患者結(jié)果的前瞻性、多站點研究。
11.Long COVID after breakthrough SARS-CoV-2 infection.
突破性SARS-CoV-2感染后的長COVID。
12.Modeling transmission of SARS-CoV-2 Omicron in China.
中國SARS-CoV-2 Omicron的傳播模型。
13.Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals.
巴西醫(yī)院中COVID-19死亡率的空間和時間上的波動。
14.Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60?years.
第二次BNT162b2強(qiáng)化疫苗對60歲以上成人COVID-19住院和死亡的有效性。
15.Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
未接種疫苗和接種疫苗的人感染祖?zhèn)鞯?、Delta或Omicron SARS-CoV-2的傳染性病毒量。
16.Drivers of adaptive evolution during chronic SARS-CoV-2 infections.
慢性SARS-CoV-2感染期間適應(yīng)性進(jìn)化的驅(qū)動因素。
靶向泛癌RET融合
In this issue, Subbiah and colleagues report findings from ARROW, a phase 1/2 clinical trial testing pralsetinib, a tumor-agnostic inhibitor of the receptor tyrosine kinase RET, in a range of solid tumors. The cover image depicts a diverse group of patients, each with different cancers harbouring RET fusions, all treated with pralsetinib.
在本期雜志中，Subbiah及其同事報告了ARROW的發(fā)現(xiàn)，ARROW是一項1/2期臨床試驗，在一系列實體瘤中測試pralsetinib，一種與腫瘤無關(guān)的受體酪氨酸激酶RET抑制劑。封面圖片描繪了一組不同的患者，每個患者都患有不同的帶有RET融合的癌癥，所有患者都接受了pralsetinib治療。
1.CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia.
CRISPR-Cas9介導(dǎo)的BCL11A增強(qiáng)子的基因編輯用于小兒β0/β0輸血依賴性β地中海貧血癥。
2.Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.
分子分析確定了兒科實體癌的靶向治療機(jī)會。
3.Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer.
遺傳風(fēng)險評分加強(qiáng)了對兒童癌癥成年幸存者嚴(yán)重肥胖的風(fēng)險預(yù)測。
4.Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
阿特唑單抗聯(lián)合貝伐珠單抗治療晚期肝細(xì)胞癌的臨床反應(yīng)和耐藥性的分子相關(guān)因素。
5.Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
循環(huán)腫瘤DNA指導(dǎo)帕尼單抗對轉(zhuǎn)移性結(jié)直腸癌的再挑戰(zhàn)：2期CHRONOS試驗。
6.Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
個性化的異源黑猩猩腺病毒和自擴(kuò)增mRNA新抗原疫苗治療晚期轉(zhuǎn)移性實體瘤：1期試驗中期結(jié)果。
7.Intratumoral oncolytic herpes virus G47? for residual or recurrent glioblastoma: a phase 2 trial.
瘤內(nèi)溶瘤皰疹病毒G47?治療殘余或復(fù)發(fā)膠質(zhì)母細(xì)胞瘤：2期試驗。
8.Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial.
1/2期ARROW試驗中，pralsetinib對RET融合陽性實體瘤患者的泛癌療效。
9.Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
直腸癌新輔助治療反應(yīng)的基因組和轉(zhuǎn)錄組決定因素。
10.Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data.
使用大型真實世界臨床基因組學(xué)數(shù)據(jù)對突變-治療相互作用進(jìn)行系統(tǒng)的泛癌癥分析。
11.Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
慢性淋巴細(xì)胞白血病里氏轉(zhuǎn)化早期種子的檢測。
12.Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
CETP抑制劑obicetrapib聯(lián)合高強(qiáng)度他汀類藥物的降脂作用：一項隨機(jī)的2期試驗。
13.Large-scale genome-wide association study of coronary artery disease in genetically diverse populations.
遺傳多樣性人群中冠狀動脈疾病的大規(guī)模全基因組關(guān)聯(lián)研究.
14.Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes.
全球80-80-80血壓目標(biāo)和心血管疾病結(jié)果的建模。
15.City-level impact of extreme temperatures and mortality in Latin America.
拉丁美洲極端氣溫和死亡率的城市級影響.
16.Symptoms and risk factors for long COVID in non-hospitalized adults.
非住院成人長COVID的癥狀和風(fēng)險因素。
17.Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
通過遺傳距離分析快速評估COVID-19疫苗對SARS-CoV-2變種的癥狀性感染的有效性。
優(yōu)化微生物群移植
Two papers in this issue from Bork et al. and Segata et al., respectively, explore factors of donor and recipient microbiomes that drive engraftment of fecal microbiota transplantation (FMT) and the effects of this dynamic process on clinical outcomes. Donor and recipient gastrointestinal tracts and their microbiomes are represented on the cover as converging pipes, demonstrating the interplay between the microbial communities after FMT, described in Bork et al.
本期的兩篇論文來自Bork等人和Segata等人，他們分別探索了驅(qū)動糞便微生物群移植(FMT)植入的供體和受體微生物組的因素，以及這一動態(tài)過程對臨床結(jié)果的影響。供體和受體胃腸道及其微生物組在封面上表示為會聚管道，展示了FMT后微生物群落之間的相互作用，如Bork等人所述。
1.Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein.
嵌合型Gas6融合蛋白對淀粉樣蛋白的抗炎清除。
2.Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.
將分泌GDNF的人類神經(jīng)祖細(xì)胞移植到ALS患者的脊髓中：一個1/2a期試驗。
3.Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.
基于智能手機(jī)的心房顫動篩查：一項務(wù)實的隨機(jī)臨床試驗。
4.Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Atezolizumab與化療在基于血液的高腫瘤突變負(fù)擔(dān)的晚期或轉(zhuǎn)移性NSCLC中的比較：BFAST隊列C隨機(jī)3期試驗的主要分析。
5.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.
Trastuzumab deruxtecan治療HER2陽性乳腺癌腦轉(zhuǎn)移：一項單臂2期試驗。
6.Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
與難治性B細(xì)胞淋巴瘤的CAR-T療法反應(yīng)有關(guān)的獨特的細(xì)胞動態(tài)。
7.Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.
灌注后的CAR TReg細(xì)胞可識別對CD19-CAR療法有抵抗力的患者。
8.Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
腫瘤免疫環(huán)境是大B細(xì)胞淋巴瘤中抗CD19 CAR T細(xì)胞療效的決定因素。
9.A digital mask to safeguard patient privacy.
保障患者隱私的數(shù)字面具。
10.Genetic risk factors have a substantial impact on healthy life years.
遺傳風(fēng)險因素對健康生活年限有很大影響。
11.Drivers and determinants of strain dynamics following fecal microbiota transplantation.
糞便微生物群移植后菌種動態(tài)的驅(qū)動因素和決定因素。
12.Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.
糞便微生物群移植后菌種移植的可變性和不同疾病的微生物群組成的可預(yù)測性。
13.Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.
以抗體為媒介預(yù)防HIV-1感染的中和滴度生物標(biāo)志物。
14.Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
南加州SARS-CoV-2 Omicron（B.1.1.529）變體和BA.1/BA.1.1或BA.2亞變體感染的相關(guān)臨床結(jié)果。
15.Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.
針對甲型流感病毒和SARS-CoV-2的關(guān)鍵保守病毒RNA二級結(jié)構(gòu)的可編程抗病毒藥物。
舉證責(zé)任
In this issue, five Burden of Proof studies from the Institute for Health Metrics and Evaluation present a new method for assessing the cumulative strength of available evidence for risk factors and associated health outcomes. Together, these papers describe the methodology and demonstrate the utility of the approach with exemplars over which the burden of proof spans a range of certainty. The magnifying glass in the cover image represents the burden of proof risk function, which enables a closer view of risk factors and the evidence for associated health outcomes.
在本期雜志中，來自健康指標(biāo)與評估研究所的五項舉證責(zé)任研究提出了一種新方法，用于評估風(fēng)險因素和相關(guān)健康結(jié)果的可用證據(jù)的累積強(qiáng)度。這些論文共同描述了方法，并通過范例證明了該方法的實用性，在這些范例中，舉證責(zé)任涵蓋了一定范圍的確定性。封面圖片中的放大鏡代表風(fēng)險函數(shù)的證明責(zé)任，可以更近距離地查看風(fēng)險因素和相關(guān)健康結(jié)果的證據(jù)。
1.The Burden of Proof studies: assessing the evidence of risk.
證明研究的負(fù)擔(dān)：評估風(fēng)險的證據(jù)。
2.Health effects associated with smoking: a Burden of Proof study.
與吸煙有關(guān)的健康影響：證明負(fù)擔(dān)的研究。
3.Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.
收縮壓升高對缺血性心臟病的影響：一項證明負(fù)擔(dān)的研究。
4.Health effects associated with vegetable consumption: a Burden of Proof study.
與蔬菜消費相關(guān)的健康影響：一項證明負(fù)擔(dān)的研究。
5.Health effects associated with consumption of unprocessed red meat: a Burden of Proof study.
與未加工的紅肉消費相關(guān)的健康影響：證明負(fù)擔(dān)的研究。
6.Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Semaglutide對成人超重或肥胖癥的兩年效果：STEP 5試驗。
7.Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
胰高血糖素受體拮抗劑volagidemab治療1型糖尿?。阂豁棡槠?2周的隨機(jī)、雙盲、2期試驗。
8.Microbiome-derived ethanol in nonalcoholic fatty liver disease.
非酒精性脂肪肝中微生物衍生的乙醇。
9.Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.
利用電子健康記錄中的合并癥簽名篩查特發(fā)性肺纖維化。
10.Long-term cardiac pathology in individuals with mild initial COVID-19 illness.
輕度初始COVID-19疾病個體的長期心臟病理變化。
11.Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
抗CD19 CAR T細(xì)胞治療難治性系統(tǒng)性紅斑狼瘡。
12.KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
基于KIR的抑制性CARs克服了CAR-NK細(xì)胞細(xì)胞增多癥介導(dǎo)的自相殘殺和腫瘤逃脫。
13.A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
tisagenlecleucel和axicabtagene ciloleucel CAR T細(xì)胞在復(fù)發(fā)或難治性彌漫性大B細(xì)胞淋巴瘤中的真實世界比較。
14.Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
新輔助阿特唑侖治療可切除的非小細(xì)胞肺癌：一個開放標(biāo)簽的單臂II期試驗。
15.RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.
RNF43突變預(yù)測BRAFV600E轉(zhuǎn)移性結(jié)直腸癌對抗BRAF/EGFR組合療法的反應(yīng)。
16.Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
一種強(qiáng)效和選擇性的非共價KRASG12D抑制劑的抗腫瘤功效。
17.Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial.
Pepinemab抗體阻斷SEMA4D在早期亨廷頓病中的作用：一項隨機(jī)、安慰劑對照的2期試驗。
18.Temporal order of clinical and biomarker changes in familial frontotemporal dementia.
家族性額顳葉癡呆癥的臨床和生物標(biāo)志物變化的時間順序。
19.Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals.
利用夜間呼吸信號進(jìn)行帕金森病的人工智能檢測和評估.
代謝個性
In this issue, Langenberg and colleagues reveal the genetic architecture that underpins individualized metabolic profiles and their relationship with clinical phenotypes. The tattoos of metabolic pathways on the cover reflect the chemical individuality of the person, with the base codes in the background representing the genetics that underlie the metabolic phenotypes.
在本期雜志中，Langenberg及其同事揭示了支持個體化代謝特征的遺傳結(jié)構(gòu)及其與臨床表型的關(guān)系。封面上代謝途徑的紋身反映了人的化學(xué)個性，背景中的基本代碼代表了代謝表型背后的遺傳學(xué)。
1.Proteomic signatures for identification of impaired glucose tolerance.
識別糖耐量受損的蛋白質(zhì)組學(xué)特征。
2.Association of step counts over time with the risk of chronic disease in the All of Us Research Program.
我們所有人的研究計劃中，步數(shù)與慢性病風(fēng)險的關(guān)系。
3.Metabolomic profiles predict individual multidisease outcomes.
代謝組圖譜預(yù)測個體多發(fā)病的結(jié)果。
4.Rare and common genetic determinants of metabolic individuality and their effects on human health.
代謝個體的罕見和常見遺傳決定因素及其對人類健康的影響。
5.Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome.
微生物組、飲食和遺傳對人類血漿代謝組的個體間差異的影響。
6.Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
飲食驅(qū)動的微生物生態(tài)學(xué)支撐著癌癥免疫治療結(jié)果與腸道微生物組之間的關(guān)聯(lián)。
7.Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
循環(huán)腫瘤DNA指導(dǎo)下的晚期非小細(xì)胞肺癌治療的總生存率。
8.Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
以前接受過治療的轉(zhuǎn)移性葡萄膜黑色素瘤患者對泰賓達(dá)夫的臨床和分子反應(yīng)：2期試驗。
9.Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Cemiplimab加化療與單純化療治療非小細(xì)胞肺癌：一項隨機(jī)、對照、雙盲的3期試驗。
10.Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
淀粉樣蛋白和tau蛋白PET陽性的無認(rèn)知障礙者未來認(rèn)知能力下降的風(fēng)險很高。
11.Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
含有二價Beta的COVID-19加強(qiáng)型疫苗的安全性、免疫原性和抗體持久性：2/3期試驗。
12.Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
與SARS-CoV-2再感染相關(guān)的急性和急性期后遺癥。
13.Long-term neurologic outcomes of COVID-19.
COVID-19的長期神經(jīng)系統(tǒng)結(jié)果。
14.Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
回顧性地模擬增加全球疫苗共享對COVID-19大流行的影響。
15.Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
3BNC117和羅米地辛在HIV-1患者開始抗逆轉(zhuǎn)錄病毒治療時的早期干預(yù)：一個1b/2a期的隨機(jī)試驗。
tau蛋白病的生物標(biāo)志物
In this issue, Sato and colleagues tested the ability of isoform-specific tau species in cerebrospinal fluid (CSF) to distinguish different subtypes of primary tauopathies. The left and right sides of the tree portray the pathological and healthy brain, respectively, populated with leaves of tau isoforms, with the falling leaves being isoforms represented in the CSF.
在本期雜志中，Sato及其同事測試了腦脊液（CSF）中同工型特異性tau物種區(qū)分原發(fā)性tau病不同亞型的能力。樹的左側(cè)和右側(cè)分別描繪了病態(tài)和健康的大腦，其中布滿了tau亞型的葉子，落葉是CSF中代表的亞型。
1.Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction.
對智能手表檢測左心室功能障礙的前瞻性評估。
2.Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
Dapagliflozin治療射血分?jǐn)?shù)改善的心衰：DELIVER試驗的特定前分析。
3.Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
恩帕里氟辛在保留射血分?jǐn)?shù)的心力衰竭中的療效：EMPEROR-Preserved的特定前分析。
4.Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality.
可穿戴設(shè)備測量的劇烈間歇性生活方式體力活動與死亡率的關(guān)系。
5.Efficacy of supermarket and web-based interventions for improving dietary quality: a randomized, controlled trial.
基于超市和網(wǎng)絡(luò)的改善飲食質(zhì)量的干預(yù)措施的有效性：一項隨機(jī)對照試驗。
6.Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior.
與肥胖和不良行為有關(guān)的人類血清素2C受體功能喪失變體。
7.CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
CSF tau微管結(jié)合區(qū)可識別原發(fā)性tauopathies的病理變化。
8.Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.
Aβ42/40、p-tau231和p-tau217對阿爾茨海默病試驗選擇和疾病監(jiān)測的不同作用。
9.Global and regional estimates of orphans attributed to maternal cancer mortality in 2020.
2020年全球和區(qū)域范圍內(nèi)因孕產(chǎn)婦癌癥死亡而導(dǎo)致的孤兒估計。
10.Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Atezolizumab聯(lián)合基于蒽環(huán)類藥物的化療治療轉(zhuǎn)移性三陰性乳腺癌：隨機(jī)、雙盲 2b期ALICE試驗。
11.Germline variants associated with toxicity to immune checkpoint blockade.
與免疫檢查點阻斷療法的毒性有關(guān)的種系變異。
12.IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
IL7基因變異與黑色素瘤患者免疫檢查點阻斷療法的毒性。
13.Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
癌癥免疫治療前和治療期間全身CD8+T細(xì)胞可視化：1/2期試驗。
14.Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
早期治療的HIV-1感染中HTI疫苗的安全性、免疫原性和對病毒反彈的影響：一項隨機(jī)、安慰劑對照的1期試驗。
15.Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes.
隨著年齡的增長，吸入的顆粒物積累損害了人類肺部淋巴結(jié)的免疫功能和結(jié)構(gòu)。
16.Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial.
血管生成素樣3衍生物L(fēng)NA043用于骨關(guān)節(jié)炎的軟骨再生：一項隨機(jī)的1期試驗。
17.Leukocyte telomere length in children born following blastocyst-stage embryo transfer.
囊胚期胚胎移植后出生的兒童的白細(xì)胞端粒長度。
